Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894958 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
A Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01894958 is a Phase 2 study that has completed, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 72 participants.
The verdict
NCT01894958, a Phase 2 study, has completed, sponsored by Neuren Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
Interventions
- DRUG Placebo
- DRUG NNZ-2566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894958
The ClinicalTrials.gov registry entry for NCT01894958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuren Pharmaceuticals Limited, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01894958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01894958 about?
NCT01894958 is a clinical study titled "A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome". The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
What is the current status of trial NCT01894958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01894958?
The interventions under investigation include: Placebo (DRUG), NNZ-2566 (DRUG).
Who is sponsoring clinical trial NCT01894958?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.